Archive for March, 2019

Gordon Lecture: Development of High Resolution PET Scanners with Depth Encoding Detectors


Prof. Yongfeng Yang got his Ph.D from Kyushu University, Japan in 2001. From 2002-2014 he worked at Prof. Simon Cherry’s lab at Department of Biomedical Engineering, UC Davis as postdoctoral fellow and project scientist. He has been a professor at Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences since 2015. His research interests focus on instrumentation and application of positron emission tomography. The research of his lab is currently supported by Chinese National Science Foundation and Shenzhen City. Below is his presentation summary.

Depth of interaction uncertainty of the traditional PET detectors is solely the biggest obstacle for small animal and brain PET scanners to achieve high sensitivity and high spatial resolution simultaneously. In this presentation, first Dr. Yang presented his previous work on developing dual-ended readout depth encoding PET detectors with position sensitive APDs and developing a high resolution dedicated mouse brain PET scanner. Then the current work of his lab on developing MRI compatible small animal and brain PET scanners by using dual-ended readout detectors with SiPMs will be presented.

Radiology Employee Earns Certifications in Three Areas of Research Administration


This story was originally published on 03/12/2019 by  Rad Times, a publication of the Mass General Hospital Department of Radiology.

Ramzi El Fakhri, MBA, has become the first individual in New England to be certified in all three areas of research administration, namely research finance (CFRA), pre-award (CPRA), and general/post-award administration (CRA). There are only 11 other administrators in the US who hold all three designations at the same time.

The CFRA, CPRA and CRA recognize an individual’s knowledge in research administration and increase sponsored research offices' credibility. The minimum requirements for each designation are a bachelor’s degree, three years of relevant professional experience, and the successful completion of a national and rigorous exam organized by the Research Administrators Certification Council (RACC).

Ramzi manages a portfolio of grants and the PET Core research facility at the MGH Gordon Center where he has worked for the past three and half years.

Ramzi El Fakhri

TED-Ed video: why do hospitals have particle accelerators?


Gordon Center Assistant Professor Pedro Brugarolas collaborated with TED-Ed to explain the science behind how doctors use radioactive drugs and PET scans to detect and diagnose diseases like Alzheimer’s and cancer.

Gordon Lecture: Development of Copper(II)-Mediated Methods for PET Imaging Applications


Ms. Katarina J. Makaravage completed her B.S. in Chemistry at Appalachian State University in 2014. She is currently completing her PhD at the University of Michigan under the direction of Prof. Melanie Sanford. She has focused on developing new methodologies for PET imaging applications in collaboration with Prof. Peter Scott from the University of Michigan Radiology Center. Ms. Makaravage was the guest speaker at a lecture organized by the MGH Gordon Center. Below is her presentation summary.

Most positron emission tomography (PET) imaging studies are performed with fluorine-18 as the positron emitting radionuclide. Creating a C(sp2)–F bond is difficult, but several late-stage methods have been developed that overcome the challenges presented by this transformation. Unfortunately, translating methods for making natural C(sp2)–19F bonds to forging radioactive C(sp2)–18F moieties is not trivial due to several factors that will be discussed. The first section of this talk focused on the development of organometallic reagents commonly employed in the PET community to make C(sp2)–18F bonds. The starting materials required for these methods are frequently utilized, making the incorporation of this new methodology an easier transition. The second segment of this presentation discussed the application of these methodologies to improve the overall synthesis of 4-[18F]fluoro-m-hydroxyphenethylguanidine ([18F]4F-MHPG), a cardiac imaging agent currently going through clinical trials. Ms. Makaravage's talk addressed several challenges her group faced during the development of these methods, their current status, and future methodological developments.